About Maan Pharmaceuticals Ltd
Data last updated: 07 July 2026
Maan Pharmaceuticals Ltd is a public limited company based in Ahmedabad, Gujarat, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 13 May 1988, the company has been in operation for over 38 years.
Registered with ROC Ahmedabad under CIN U24231GJ1988PLC010699.
Capital: an authorised share capital of ₹7.5 Cr and a paid-up capital of ₹7.14 Cr. Formerly known as Maan Pharmaceuticals P Ltd. It is led by directors including Lalbhai Maljibhai Desai and Hemendra Atmaram Patel.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Ahmedabad, Gujarat.
As per the financials filed for FY 2025, the company reported a revenue of ₹101.88 Cr, a decline of 4% compared to the previous year.
The company has a workforce of approximately 27 employees as per the latest available data.
The company is associated with 1 brand - Maan Pharmaceuticals. As per MCA filings, the company has open charges of ₹49.88 Cr and satisfied charges of ₹83.61 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website maanpharma.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered Address506 Samedh Near Associated Petrol Pump C.G.Road Ell, Isbridge, Ahmedabad, Gujarat, India – 380006
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Maan Pharmaceuticals Ltd
Maan Pharmaceuticals Ltd operates one associated brand: Maan Pharmaceuticals. These brands represent Maan Pharmaceuticals Ltd's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical company specializing in de-addiction treatments and global operations. | maanpharma.com |
Business Activity of Maan Pharmaceuticals Ltd
Maan Pharmaceuticals Ltd is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Maan Pharmaceuticals Ltd
Maan Pharmaceuticals Ltd is audited by ASHISH B. SHAH & ASSOCIATES for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| ASHISH B. SHAH & ASSOCIATES | blur-value | blur-value | blur-value |
Board of Directors of Maan Pharmaceuticals Ltd
Maan Pharmaceuticals Ltd is currently managed by 5 directors, with 10 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Lalbhai Maljibhai Desai | Director | 01 May 2013 | 13 Years 2 Months | Current |
| Hemendra Atmaram Patel | Director | 01 Apr 2011 | 15 Years 3 Months | Current |
|
Nilesh Narendrakumar Ranka
Also directs:
Nivo Lifesciences Private Limited, Veritas Bioventions Private Limited, Medicef Pharma Limited and 1 more
|
Director | 10 Jul 2013 | 13 Years 0 Months | Current |
|
Anil Hari Bhambhani
Also directs:
Gandhinagar Hospitalities Private Limited
|
Director | 30 Sep 2024 | 1 Years 9 Months | Current |
| Vishnu Motibhai Desai | Director | 30 Oct 2024 | 1 Years 8 Months | Current |
Financials of Maan Pharmaceuticals Ltd FY 2025 filings available
Maan Pharmaceuticals Ltd reported revenue of ₹101.88 Cr (down 4% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Maan Pharmaceuticals Ltd
As of FY 2024, Maan Pharmaceuticals Ltd's shareholding pattern shows 69.22% by promoters, 30.79% by public shareholders. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Maan Pharmaceuticals Ltd
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 Jul 2025 | Yes Bank Limited | ₹49.88 Cr | Open |
| 07 Aug 2020 | Others | ₹2.4 Cr | Satisfied |
| 16 Oct 2017 | Others | ₹17 Cr | Satisfied |
| 10 Mar 2016 | Others | ₹3 Cr | Satisfied |
| 26 Mar 2013 | The Mehsana Urban Co-Operative Bank Limited | ₹4 Cr | Satisfied |
Total charge records: 15 View all charges
Employees and EPFO Compliance at Maan Pharmaceuticals Ltd
Maan Pharmaceuticals Ltd has a workforce of 27 employees as of Feb 26, 2025.
Employee Count & EPFO Data of Maan Pharmaceuticals Ltd
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Maan Pharmaceuticals Ltd
GSTIN & GST Filing Data of Maan Pharmaceuticals Ltd
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Maan Pharmaceuticals Ltd
Credit Ratings, Legal Cases & Regulatory Alerts of Maan Pharmaceuticals Ltd
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Maan Pharmaceuticals Ltd
MSME Payment Delays by Maan Pharmaceuticals Ltd
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Maan Pharmaceuticals Ltd
Subsidiaries & Group Companies of Maan Pharmaceuticals Ltd
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Maan Pharmaceuticals Ltd with ownership details.
MCA Filings & Documents of Maan Pharmaceuticals Ltd
MCA Filings & Documents of Maan Pharmaceuticals Ltd
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Maan Pharmaceuticals Ltd
Recent News on Maan Pharmaceuticals Ltd
Frequently Asked Questions about Maan Pharmaceuticals Ltd
Maan Pharmaceuticals Ltd is an active public limited company in the pharma sector based in Ahmedabad, Gujarat, India. It was incorporated on 13 May 1988 (38+ years old) and is registered under CIN U24231GJ1988PLC010699. The company has 27 employees.
Maan Pharmaceuticals Ltd reported revenue of ₹101.88 Cr for FY 2025 (down 4.00% YoY).
The current directors of Maan Pharmaceuticals Ltd are:
The primary industry of Maan Pharmaceuticals Ltd is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Maan Pharmaceuticals Ltd can be reached at the registered office: 506 Samedh Near Associated Petrol Pump C.G.Road Ell, Isbridge, Ahmedabad, Gujarat, India – 380006, or through the website maanpharma.com.
The authorised capital is ₹7.5 Cr, and the paid-up capital is ₹7.14 Cr.